GLP-1 Drugs and Muscle Loss: How to Protect Lean Mass

The number most people on GLP-1s aren't told

You've been tracking the scale. You're down 18 pounds. Your clothes fit differently. Everything looks like a win.

But the STEP trials — the large clinical studies that supported FDA approval of semaglutide — also showed that a significant portion of that weight loss doesn't come from fat. In a 2024 review published in PubMed, lean body mass comprised 26–40% of total weight lost across GLP-1-based therapies. In practical terms: if you've lost 20 lbs, somewhere between 5 and 8 of those pounds may have been muscle.

That's not a reason to stop. But it is a reason to pay attention to something the initial prescribing conversation often skips entirely.

Why muscle mass matters more than the scale suggests

Muscle isn't just aesthetics. It's metabolic infrastructure.

Lean mass drives your resting metabolic rate, meaning more muscle means more calories burned at rest. It protects your joints, supports bone density, and strongly predicts long-term metabolic health — particularly in women, where muscle mass declines naturally from the late 30s onward and accelerates with menopause.

Losing substantial lean mass during GLP-1 treatment can set you up for a slower metabolism after treatment ends, making weight maintenance significantly harder. A 2026 analysis in Harvard Science Review flagged this directly: muscle loss during GLP-1 treatment may accelerate certain cellular aging markers, particularly in the context of rapid weight loss.

What actually protects lean mass on GLP-1s

Two strategies have the most consistent evidence: resistance training and protein intake. Both are unsurprising in theory. The challenge is application — because GLP-1 drugs suppress appetite significantly, and many women end up eating far less protein than their body needs to maintain muscle.

Protein: the intake most women underestimate

General dietary guidance often puts protein at 0.8g per kilogram of bodyweight. That floor was set for sedentary populations to prevent deficiency — not to preserve muscle during active weight loss.

Research on weight loss contexts consistently points to higher targets. Across multiple studies of caloric restriction and weight management, protein intakes of 1.2–1.6g per kilogram of bodyweight are associated with better lean mass preservation. In the ENDO 2025 data on GLP-1 users specifically, higher protein intake was highlighted as the most accessible mitigation strategy available.

The practical problem: if semaglutide has dropped your appetite to 1,400 calories a day, hitting 100+ grams of protein requires deliberate prioritization of protein-dense foods at every meal. It won't happen passively.

Resistance training: not optional, not gentle

Cardio burns calories. Resistance training signals your body to preserve and build muscle. These are fundamentally different things, and GLP-1 treatment is a context where the distinction matters.

The American Council on Exercise published a dedicated guide in 2025 specifically for GLP-1 users, recommending multi-joint resistance movements — squats, deadlifts, rows, presses — with progressive overload, at least twice per week. The goal isn't cardiovascular fitness. It's sending a metabolic signal that lean mass is worth keeping.

If you're new to resistance training or returning after a gap, working with a trainer who understands body composition — not just general fitness — is worth the investment.

What the next generation of GLP-1 drugs is doing about this

Muscle loss isn't a secret in the GLP-1 field. Researchers and pharmaceutical companies are actively working on it.

The most striking early data comes from trials combining semaglutide with bimagrumab, an experimental drug that acts on the activin type II receptor to block muscle wasting signals. In early trials, participants taking both drugs showed 100% of weight loss coming from fat — with a concurrent increase in lean muscle mass of more than 2%. That's a meaningfully different body composition outcome than semaglutide alone.

Bimagrumab is not yet approved or commercially available. But it signals where the science is going.

Separately, researchers at the American Diabetes Association presented data in 2025 showing that newer GLP-1/GIP dual agonists (like tirzepatide) may offer somewhat better lean mass preservation than semaglutide alone — though the differences were modest, and resistance training still outperformed medication differences in the data.

The honest version of this conversation

GLP-1 medications are genuinely effective. The cardiovascular outcomes data from STEP and SURMOUNT trials is real, and for many women, the benefits far outweigh the lean mass tradeoff — especially when that lean mass loss is partially offset with exercise and adequate protein.

The problem is that most prescribers hand over the medication without handing over this information. You might be told to "eat protein and exercise." You're rarely told specifically why lean mass matters, what percentage of your weight loss may be muscle, or what protein targets actually look like at a suppressed appetite.

That gap is the part worth closing. The drug is doing its job. The question is whether you're set up to get the best version of the outcome from it.